Luisa Escobar-Hoyos, MSc, PhD

The Escobar-Hoyos Lab at Yale School of Medicine develops innovative, targeted therapies for pancreatic and lung cancers. The team investigates somatic mutations and aberrant RNA processing, pioneering "splicing-hit oligo therapy" (SHOT), a personalized medicine approach correcting cancer-specific splicing errors. With the goal of developing new treatments for these challenging cancers, her research on keratin 17 (K17) has led to a novel vaccine approach. This approach is designed to harness the potential of patients' pre-existing immunity to common bacterial infections. Using cutting-edge proteomics, transcriptomics, and cellular and biochemical techniques, Dr. Escobar-Hoyos’ team translates these mechanistic discoveries into clinical applications, striving to cure these devastating diseases.